Eli Lilly, AbbVie in M&A action; Gilead’s oncology deal spree; FDA puts its foot down on Makena; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
I was somewhat detached from the news this week to work on a reporting project, so putting this weekly together was an especially helpful exercise in reviewing what happened. If it does the same for you, please do spread the word — or let us know what we can do better.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.